http://jppbr.ub.ac.id/
DOI: 10.21776/ub.jppbr.2024.005.01.1
eISSN: 2723-083X pISSN: 2723-0821
Journal of Psychiatry Psychology and
Behavioral Research
Vol. 5 No. 1, March 2024
JPPBR
PREVALENCE OF METABOLIC SYNDROME AMONG
PATIENTS WITH SCHIZOPHRENIA FROM LONG CARE
UNIT IN FORENSIC PSYCHIATRY PROGRAM: AN
OBSERVATIONAL STUDY
Javed Ather Siddiqui, 1, 3 Shazia Farheen Qureshi, 2, 3 Hani Matrok Alotaibi, 3, 4 Waleed Mohsen Alkhammash. 3, 4
Correspondence: javedsiddiqui2000@gmail.com
of Psychiatry, Seth Gordhandas Sunderdas Medical College and the King Edward Memorial Hospital, Mumbai 400012, India; 2
Department of Psychiatry, College of Physicians and Surgeons of Bombay, Mumbai 400012, India; 3 Department of Psychiatry, Eradah &
Mental Health Complex - Taif, 21944, Saudi Arabia; 4 Saudi Board of Psychiatry, Saudi Arabia.
1Department
RESEARCH
OPEN ACCESS
ABSTRACT
Introduction – Metabolic syndrome is a leading health concern among schizophrenia patients treated with antipsychotics. The morbidity and
mortality rates of these patients can increase when they already have cardiovascular disease and other risk factors. This study aimed to examine
the prevalence of metabolic syndrome and its relationship to various clinical parameters such as blood pressure, fasting blood glucose,
triglycerides, high-density lipoprotein, and waist circumference.
Methods – This disease-oriented observational study was carried out in the forensic psychiatric rehabilitation ward at the Erada & Mental
Health Complex - Taif, Saudi Arabia. Patients admitted to the inpatient ward between 2018 and 2023 participated in the study (N = 71). The
relationship between metabolic syndrome and psychotropic medications was also examined. Schizophrenia was defined by the Diagnostic
and Statistical Manual of Mental Disorders (DSM-5-TR) criteria. Metabolic syndrome was assessed based on the international criteria
National Cholesterol Education Program’s Adult Treatment Panel III report (ATPIII) criteria and AHA/NHLB.
Results – In this study, 71 volunteer schizophrenic patients were included, and an observational study over five years was conducted. We
found the total number of metabolic syndrome patients was 40 (56.34%) compared with 31 (43.66%) patients without metabolic syndrome.
The majority of metabolic syndrome patients (57.50%) were aged 41 to 50. The highest number of patients suffering from metabolic syndrome
are those taking atypical antipsychotic medications. Among antipsychotic medications, aripiprazole was found the maximum number of 10
(25%) followed by olanzapine 7 (17.5%). Maximum number of metabolic syndrome parameters increased fasting blood sugar 26 (65%)
followed by increased body mass index 21 (52.5%).
Discuss – This research can contribute to the study of the prevalence of metabolic syndrome among patients with schizophrenia. In the present
study, the prevalence of metabolic syndrome was 56.34 percent in schizophrenia. There are several metabolic side effects associated with
second-generation antipsychotics and if these aren't treated properly, they can lead to serious health complications, such as diabet es,
dyslipidemia, and fatal heart disease.
Conclusion - In our study, metabolic syndrome was most prevalent among patients between 41 - 50 years of age. Therefore, clinicians are
encouraged to screen and monitor metabolic syndrome and treat cardio-metabolic risk factors for optimum long-term management.
Keywords: schizophrenia, metabolic syndrome, antipsychotics.
Article History:
Received: February 6, 2024
Accepted: March 4, 2024
Published: March 31, 2024
Cite this as: Siddiqui, J.A, Qureshi, S.F., Alotaibi, H.M., Alkhammash, W.M. Prevalence of Metabolic Syndrome
Among Patients with Schizophrenia from Long Care Unit in Forensic Psychiatry Program: an Observational
Study. Journal of Psychiatry Psychology and Behavioral Research; 2024.5:1. p1-6.
schizophrenia patients has been reported in numerous studies.
The prevalence of metabolic syndrome is estimated to be 30
percent in patients with psychotic disorders,3 10 percent in
diabetes mellitus,4 and 20 percent in hypertension.5 A
metabolic syndrome diagnosis is made based on the criteria in
the Adult Treatment Panel III report (ATPIII) of the National
Cholesterol Education Program. It was defined as metabolic
syndrome when three or more of the following conditions were
present in a subject: Waist Circumference(WC ≥102) cm in
INTRODUCTION
The metabolic syndrome refers to a group of conditions,
including diabetes, hypertension, dyslipidemia, and obesity
that may increase cardiovascular disease risk.1 It is
characterized by several variables, including central obesity,
high blood pressure, low levels of high-density lipoprotein
(HDL) cholesterol, elevated triglycerides, and elevated blood
sugar levels.2 The prevalence of metabolic syndrome among
1
2
men and ≥88 cm in women, Triglycerides (TG≥150) mg/dl,
High-density lipoprotein cholesterol (HDL-C <40) mg/dl in
men and <50 mg/dl in women; elevated blood pressure
(systolic ≥130 and/or diastolic ≥85 mm Hg; antihypertensive
drug treatment in a patient with a history of hypertension was
used as an alternate indicator); and elevated fasting
glucose≥100.6
In schizophrenia, the most common cause of death is
cardiovascular disease.7 A sedentary lifestyle, genetic
vulnerability, smoking, and antipsychotic medication are
associated with a higher cardiovascular mortality rate among
schizophrenic patients.8 The prevalence of metabolic
syndrome is increased by antipsychotic-induced weight gain.9,
10
There are several metabolic side effects associated with
second-generation antipsychotics and if these aren't treated
properly, they can lead to serious health complications, such as
diabetes, dyslipidemia, and fatal heart disease.11 Predisposing
risk factors for metabolic syndrome in schizophrenia patients
include long-term antipsychotic medication use, poor diet, and
low physical activity.12 It is therefore imperative to study the
prevalence of metabolic syndrome in specific contexts to
decrease physical health comorbidities and consequential
premature deaths. The metabolic syndrome has been linked to
cognitive and functional impairments in recent clinical studies.
13, 14
The risk of metabolic syndrome is higher in schizophrenia
patients who have been ill for more than 10 years,15 and those
who take antipsychotic treatment for more than 6 months.16
The majority of these studies do not examine the clinical
variables that may contribute to metabolic syndrome in
schizophrenia patients taking antipsychotics. Thus, the present
study aims to investigate whether antipsychotic medication
users are at risk for metabolic syndrome. It also studies its
association with socio-demographic factors and clinical
variables.
METHOD
Participants
Study participants included male inpatients unit at the Eradah
& Mental Health Complex - Taif, Saudi Arabia, who were in
the rehabilitation forensic psychiatry wards. Participants were
all on psychotropic medications for five years, from April 2018
to May 2023.
Parameters
A semi-structured proforma was used to evaluate the sociodemographic and clinical characteristics of patients using
psychotropic medications. We also evaluated the association
between metabolic syndrome and psychotropic medications.
We also collected data on metabolic syndrome by interviewing
patients who take psychotropic medications. Furthermore, we
conducted physical examinations and collected laboratory data
over the last five years.
Inclusion criteria
1. A group of diagnosed psychiatric cases based on the
Diagnostic and Statistical Manual of Mental
Disorders (DSM-5-TR) diagnostic criteria, in which
adult patients received psychotropic medications such
as antidepressants, antipsychotics, and mood
stabilizers.
2. Patients who have participated in the study are from
the chronic forensic rehabilitation unit.
3.
All participants who took psychotropics during the
past five years were included in the study.
Exclusion criteria
1. Female patients.
2. Age range of participants below 30 years.
Sampling technique
Researchers used a purposeful sampling strategy to select
participants from the mental health hospital in Taif, Saudi
Arabia. The sample size was N = 71, which included only male
participants. Metabolic syndrome variables such as WC ≥102
cm in men and ≥88 cm in women, TG≥150 mg/dl (drug
treatment for elevated triglycerides was used as an alternate
indicator), HDL-C <40 mg/dl in men and <50 mg/dl in women;
elevated blood pressure (systolic ≥130 and/or diastolic ≥85
mm Hg studied in schizophrenic patients those are taking
psychotropic medications.
We determine the prevalence of metabolic syndrome in
schizophrenic patients over the last five years. The study
included all inpatients meeting the inclusion criteria who were
diagnosed with a psychiatric illness and receiving psychotropic
medications, or a combination of these psychiatric
medications.
Research instrument
An objective of this study was to determine the sociodemographic profile and variables of metabolic syndrome
among the study population in conjunction with psychotropic
drugs, as well as combinations of these drugs. Researchers
filled out these forms while observing and evaluating patients
receiving psychotropic medications in metabolic syndrome.
Ethical issues in research
This study was approved by the Ethical Committee of the
Research and Studies Department, Directorate of Health
Affairs, Taif, Saudi Arabia. IRB Registration Number with
KACST, KSA: HAP-02-T-067, approval number: 874.
Data analysis and methodology
Microsoft Excel software was used to perform the statistical
analysis. The categorical variables were observed as frequency
and percentage using descriptive statistical analysis. After
obtaining written informed consent, all patients age 31 to 65
who were taking psychotropic medications were interviewed.
Consent was obtained in Arabic, which the patient understood,
and they were free to accept or reject the study. During this
study, a self-designed questionnaire was used to gather general
information. It also contributes to data collection and covers
study objectives. In the study of 71 patients taking
psychotropic medications. 40 had metabolic syndrome, while
31 displayed normal laboratory findings without metabolic
syndrome.
RESULT
This study was conducted in the chronic rehabilitation ward in
the forensic psychiatric department. The total number of
psychiatric patients monitored was 71, of which 40 patients
had metabolic syndrome (56.34 %) and 31 patients were
normal, as shown in Figure 1. The baseline and demographic
characteristics of the patients are shown in Table 1. Among 40
3
patients suffering from metabolic syndrome, 23 (57.5%) were
between the ages of 41-50, followed by 9 (22.5%) who were
more than 50 years old, and 8 (20%) were between the ages of
31- 40 years. All of the patients in the study were males. The
prevalence of metabolic syndrome was slightly higher in
married patients 36 (50.70%) than in unmarried patients 35
(49.30%).
PREVALENCE OF METABOLIC SYNDROME
100%
100%
56,34%
43,66%
100%
40
31
71
99%
99%
98%
98%
Metabolic
syndrome
Normal
Total
Participants
Frequency
Percentage
Figure 1. Prevalence of metabolic disorders in psychotropic medications taking patient.
Table 1. Distribution of total subjects by socio-demographic
characteristics.
Age distribution
Age in Years
20-30
31-40
41-50
>50
Total N=40
Frequency
0
8
23
9
40
Percentage
0
20
57.5
22.5
56.34%
Male
(Metabolic syndrome)
40
56.34
Male
(Normal)
31
43.66
Female
Total N=71
0
71
0
100%
Married
Unmarried
Total N=71
36
35
71
50.7
49.3
100%
Occupation
Employed
Unemployed
Total N=71
16
55
71
22.23
78.87
100%
Table 2. Association between type of antipsychotics and
metabolic syndrome
Types of single antipsychotics cause metabolic syndrome
Antipsychotics
Aripiprazole
Clozapine
Haloperidol
Olanzapine
Quetiapine
Risperidone
Amisulpiride
Paliperidone
Gender
Percentage (%)
25
10
7.5
17.5
5
7.5
12.5
10
TOTAL
100%
Combinations of antipsychotics cause metabolic syndrome
Marital Status
No of substances
Amisulpiride +
Aripiprazole
Risperidone +
Aripiprazole
Table 3. Variable (parameters) of metabolic syndrome
Variable (parameters) of metabolic syndrome
Variables
Elevated body mass index (BMI)
Low level of High-density lipoprotein
cholesterol (HDL-C)
Triglycerides (TGL)
Frequency
21
9
Percentage (%)
52.5
22.5
18
45
Elevated systolic blood pressure (SBP)
15
37.5
Elevated systolic blood pressure (SBP)
8
20
Elevated fasting blood glucose (FBS)
26
65
TOTAL
Frequency
10
4
3
7
2
3
5
4
100%
Frequency
3
Percentage (%)
7.5
1
2.5
The prevalence of metabolic syndrome among patients with
schizophrenia treated with antipsychotics is shown in Table 2.
Maximum numbers of patients were taking atypical
antipsychotic medication 39 (97.5%), as compared with typical
antipsychotic medication 3 (7.5%). Among atypical
antipsychotic medications, aripiprazole was found in
maximum numbers 10 (25%) followed by olanzapine 7
(17.5%), then amisulpride 5 (12.5%), clozapine and
paliperidone 4 (10%) respectively. Medications with more
than one psychotropic were those taking amisulpride with
aripiprazole 3 (7.5%) followed by 1 (2.55) risperidone with
aripiprazole taking patients.
Table 3 shows the various clinical parameters of metabolic
syndrome participants. Among patients with increased fasting
blood sugar 26 (65.0%) and increased body mass index 21
(52.5%) were diagnosed with diabetes mellitus. Increased
systolic blood pressure was found among 15 patients with 37.5
percent diagnosed with hypertension. There were 18 patients
with a high triglyceride level of 45 percent, and 9 patients with
a low level of high-density lipoprotein (HDL-C) cholesterol of
22.5 percent who were diagnosed with dyslipidemia.
discrepancies occur. A metabolic syndrome is characterized by
obesity, hypertension, and dyslipidemia, which raises the risk
of type 2 diabetes mellitus and cardiovascular disease.
Metabolic syndrome is estimated to be present in a large
majority of patients with type 2 diabetes or impaired glucose
tolerance.20 In our study similar findings noted the maximum
number of patients suffering from diabetes mellitus with 65
percent, followed by dyslipidemia and hypertension. In our
study, all participants were male patients, despite the
prevalence rates of the metabolic syndrome being noted in both
genders.
The precise causes of metabolic syndrome prevalence in
schizophrenia patients are unknown but some mechanisms
have been proposed. Poor dietary habits and a sedentary
lifestyle in these patients can increase the risk of obesity,
particularly abdominal obesity, due to the side effects of
antipsychotic medications.21, 22 In our study patients were in a
chronic rehabilitation ward with poor dietary habits and
decreased physical activity. As a result, metabolic parameters
increased day by day, supporting this hypothesis.
As reported in other studies, schizophrenia patients had a
higher incidence of diabetes than the general population. 23, 24
In our study, the majority of patients with increased fasting
blood sugar 26 (65.0%), followed by increased body mass
index 21 (52.5%) were diagnosed with diabetes mellitus.
DISCUSS
This was a hospital-based observational study carried out on
patients diagnosed with schizophrenia attending the
psychiatric male inpatient unit at the Erada & Mental Health
Complex - Taif, Saudi Arabia. These patients were in the
rehabilitation forensic psychiatry wards. The study was mainly
done to assess the prevalence and correlates of metabolic
syndrome among patients with schizophrenia treated with
antipsychotic medications. Several clinical implications
should be followed. First, there is an urgent need to develop
clinical interventions including diet and physical activity to
reverse and control metabolic abnormalities in schizophrenia
cases. Second, to establish a system for continuous monitoring
and surveillance of metabolic abnormalities in schizophrenia
cases. Mental health institutions and family physicians must
collaborate to address these implications. Thirdly, to promote
awareness about metabolic syndromes and to encourage
mental health staff to consider patients with schizophrenia and
related disorders' physical health. To prevent metabolic
syndrome, future research needs to focus on its causes.
Various studies have been conducted on the prevalence of
metabolic syndrome in Vietnam17 and Australia,18 which found
a high prevalence of 68% and 86%, respectively. A few studies
have examined metabolic syndrome in cases of schizophrenia
in Arab patients. A cross-sectional study of 63 cases in Egypt
found a 38% prevalence of metabolic syndrome based on IDF
diagnostic criteria.19 However, in our sample, we found that
the metabolic syndrome prevalence rate is 56.34%. It may be
because patients live different lifestyles that these
Limitations and suggestions for future research
This was disease-oriented observational study was carried out
in the forensic psychiatric rehabilitation ward at the Mental
Health Hospital, Taif, Saudi Arabia. This study was carried out
in the forensic chronic rehabilitation unit for the first time, and
it will help lower potential risks in the future. There are some
limitations of this research study. The study's limitations are as
follows (1) female participants were not included in this study,
as it was done on the male chronic rehabilitation ward; (2)
There was no control group. Hence, it is difficult to generalize
this finding to the general population.
Initially, it should be noted that this is an observational study,
and longer-term research is required to fully evaluate the
impact of psychiatric medication on metabolic syndrome, so
longitudinal studies are needed. In this research study the
prevalence of metabolic syndrome was found high because of
the small sample size. Therefore, further study with a large
number of patients is required to figure out the prevalence of
metabolic syndrome in these individuals. In the future,
glycated hemoglobin (HbA1c) measurements could be made
to get a more accurate assessment of the prevalence of diabetes
mellitus in the research environment. Finally, the majority of
the patients were using aripiprazole and olanzapine, which
made it difficult to determine how different antipsychotics
affected the risk of metabolic syndrome and its components in
this specific setting.
CONCLUSION
be implemented. It was found that metabolic syndrome is more
prevalent in schizophrenia patients and those taking
antipsychotics of the second generation. A physician should
monitor metabolic parameters such as waist circumference
regularly, as well as check for medication-related weight gain.
Furthermore, antipsychotics should be changed whenever
necessary to prevent an increase in mortality.
In schizophrenia patients with metabolic syndrome, high waist
circumference and low HDL are common after six months of
antipsychotic medication. As a result, patients with
schizophrenia taking multiple medications should be regularly
monitored to determine if they are suffering from metabolic
syndrome. It is important to consider risk factors among
schizophrenia patients who are taking antipsychotic
medication, and nutrition and lifestyle interventions must also
4
5
Conflict of interest
The authors declared there was no conflict of interest.
Author contribution
JAS- material preparation, conception and design, or
acquisition of data, or analysis and interpretation of data, SFQdraft of the manuscript was written, drafting or revising it
critically for significant intellectual content. HMA & WMACritical review and editing of the final manuscript was done.
Acknowledgments
Especially thanks to the Unit Manager of nursing staff of
Department of Forensic Psychiatry Ali Saud Alnefei and the
team of our hospital for providing support in arranging this
study.
REFERENCES
1. Rezaianzadeh A, Namayandeh SM, Sadr SM. National
Cholesterol Education Program Adult Treatment Panel III
Versus International Diabetic Federation Definition of
Metabolic Syndrome, Which One is Associated with
Diabetes Mellitus and Coronary Artery Disease? Int J Prev
Med.
2012;
3(8):552–558.
https://pubmed.ncbi.nlm.nih.gov/22973485/
2. Kaur J. A comprehensive review on metabolic syndrome.
Cardiol
Res
Pract.
2014;2014(943162):1-21.
https://doi.org/10.1155/2014/943162.
3. Mitchell AJ, Vancampfort D, Sweers K, Winkel R van, Yu
W, Hert MD. Prevalence of Metabolic Syndrome and
Metabolic Abnormalities in Schizophrenia and Related
Disorders—A Systematic Review and Meta-Analysis.
Schizophr
Bull.
2013;39(2):306.
https://doi.org/10.1093/schbul/sbr148
4. Vancampfort D, Correll CU, Galling B, Probst M, De Hert
M, Ward PB, et al. Diabetes mellitus in people with
schizophrenia, bipolar disorder and major depressive
disorder: a systematic review and large scale meta-analysis.
World
Psychiatry.
2016;
15(2):166–174.
https://doi.org/10.1002/wps.20309
5. Goldstein BI, Fagiolini A, Houck P, Kupfer DJ.
Cardiovascular disease and hypertension among adults
with bipolar I disorder in the United States. Bipolar Disord.
2009; 11(6):657–662. https://doi.org/10.1111/j.13995618.2009.00735.x
6. Grundy SM, Brewer Jr HB, Cleeman JI, et al. Definition of
metabolic syndrome: report of the national heart, lung, and
blood institute/american heart association conference on
scientific issues related to definition. Circulation. 2004;
109:
433-438.
https://doi.org/10.1161/01.CIR.0000111245.75752.C6.
7. Sweileh WM, Zyoud SH, Dalal SA, et al. Prevalence of
metabolic syndrome among patients with schizophrenia in
Palestine.
BMC
Psychiatry.
2012;
12:
235.
https://doi.org/10.1186/1471-244X-12-235.
8. Sugawara N, Yasui-Furukori N, Sato Y, et al. Prevalence
of metabolic syndrome among patients with schizophrenia
in Japan. Schizophr Res. 2010; 123: 244-250.
https://doi.org/10.1016/j.schres.2010.08.030.
9. Hennekens CH, Hennekens AR, Hollar D, Casey DE.
Schizophrenia and increased risks of cardiovascular
disease. Am Heart J. 2005; 150:1115‑1121.
https://doi.org/10.1016/j.ahj.2005.02.007.
10. De Hert M, Correll CU, Bobes J, Cetkovich‑Bakmas M,
Cohen D, Asai I, et al. Physical illness in patients with
severe mental disorders. I. Prevalence, impact of
medications and disparities in health care. World
Psychiatry.
2011;10(1):52‑77.
https://doi.org/10.1002/j.2051-5545.2011.tb00014.x.
11. Siddiqui JA, Qureshi SF, Alghamdi IM, Alotaibi HM.
Metabolic syndrome: a psychiatric outlook. Psychosom
Med Res. 2023;5(1):1.
https://doi.org/10.53388/PSMR2023.
12. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of
metabolic syndrome and its components in people with
schizophrenia and related psychotic disorders, bipolar
disorder, and major depressive disorder: A systematic
review
and
meta-analysis.
World
Psychiatry.
2015;14(3):339-347. https://doi.org/10.1002/wps.20252.
13. Bora E, Akdede BB, Alptekin K. The relationship between
cognitive impairment in schizophrenia and metabolic
syndrome: A systematic review and meta-analysis. Psychol
Med.2017;47(6):1030-1040.
https://doi.org/10.1017/S0033291716003366.
14. Yates KF, Sweat V, Yau PL, et al. Impact of metabolic
syndrome on cognition and brain: A selected review of the
literature.
Arterioscler
Thromb
Vasc
Biol.
2012;32(9):2060-2067.
https://doi.org/10.1161/ATVBAHA.112.252759.
15. De Hert M, van Winkel R, Van Eyck D, Hanssens L,
Wampers M, Scheen A, et al. Prevalence of diabetes,
metabolic syndrome and metabolic abnormalities in
schizophrenia over the course of the illness: A
cross‑sectional study. Clin Pract Epidemiol Ment Health.
2006; 2:14. https://doi.org/10.1186/1745-0179-2-14.
16. Bajaj S, Varma A, Srivastava A, Verma AK. Association
of metabolic syndrome with schizophrenia. Indian J
Endocrinol
Metab.
2013;17(5):890‑895.
https://doi.org/10.4103/2230-8210.117238.
17. Ogbera AO. Prevalence and gender distribution of the
metabolic syndrome. Diabetol Metab Syndr. 2010; 2(1):1.
https://doi.org/10.1186/1758-5996-2-1.
18. 18.Tirupati S, Chua L‐E. Obesity and metabolic syndrome
in a psychiatric rehabilitation service. Aust NZ J
Psychiatry.
2007;41(7):606–610.
https://doi.org/10.1080/00048670701392841.
19. Hatata H, El Gohary G, Abd-Elsalam M, et al. Risk of
metabolic syndrome among Egyptian patients with
schizophrenia.
Curr
Psychiatry.
2010;16:85-95.
https://psychiatry-research-eg.com/texts/currentpsychiatry-v15n3-08/9en.pdf
20. Isezuo SA, Ezunu E. Demographic and clinical correlates
of metabolic syndrome in Native African type 2 diabetic
patients. J Natl Med Assoc. 2005, 97 (4): 557-563.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2568734/
21. Ryan MC, Thakore JH. Physical consequences of
schizophrenia and its treatment: the metabolic syndrome.
Life
Sci
2002;
71(3):
239-257.
https://doi.org/10.1016/s0024-3205(02)01646-6.
22. Thakore J, Mann J, Vlahos I, Martin A, Reznek R.
Increased visceral fat distribution in drug-naive and
drugfree patients with schizophrenia. Int J Obes Relat
Metab
Disord
2002;
26(1):
137-141.
https://doi.org/10.1038/sj.ijo.0801840.
23. Hanley AJ, Karter AJ, Williams K, et al. Prediction of type
2 diabetes mellitus with alternative definitions of the
metabolic
syndrome:
the
Insulin
Resistance
6
Atherosclerosis Study. Circulation 2005; 112(24): 37133721.
https://doi.org/10.1161/CIRCULATIONAHA.105.559633
.
24. Shafie S, Lee SP, Ong SBC, et al. Prevalence and correlates
of diabetes mellitus and dyslipidemia in a long-stay
inpatient schizophrenia population in Singapore. Singapore
Med
J.
2018;
59(9):
465-471.
https://doi.org/10.11622/smedj.2018020.